Canada markets closed

Akero Therapeutics, Inc. (0K4.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
8.40+0.20 (+2.44%)
At close: 08:00AM CEST
Full screen
Previous Close8.20
Open8.40
Bid0.00 x N/A
Ask0.00 x N/A
Day's Range8.40 - 8.40
52 Week Range8.20 - 25.20
Volume185
Avg. Volume15
Market Cap296.99M
Beta (5Y Monthly)0.76
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Akero Therapeutics Reports First Quarter 2022 Financial Results

    Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This YearSOUTH SAN FRANCISCO, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported first quarter financial results for the period ending March 31, 2022. “Our dedicated team continues to advance our two Phase 2b clinical tria

  • GlobeNewswire

    Akero Therapeutics to Present at Upcoming Healthcare Conferences in May

    SOUTH SAN FRANCISCO, May 02, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in the following investor conferences this month: BofA Securities 2022 Healthcare Conference: Fireside chat on Wednesday, May 11 at 8:40 a.m. PT. in Las Vegas, Nevada.H.C. Wainwright Annual Global Life Sciences C

  • GlobeNewswire

    Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

    Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This YearSOUTH SAN FRANCISCO, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial results for the period ending December 31, 2021. "Our confidence in efruxifermin’s (EFX’s) potential